GlobeNewswire by notified

Brains Bio Receives NSF’s First CBD Certification for EU GMP CBD API


The independent, third-party certification confirms that the company’s facility and EU GMP CBD products have attained NSF Certified for Sport® certification

VANCOUVER, British Columbia, Nov. 22, 2022 (GLOBE NEWSWIRE) -- Brains Bioceutical Corp ("Brains Bio" or the "Company"), a global leader in EU GMP grade Cannabidiol (CBD) has received NSF GMP certification (NSF/ANSI 173, Section 8) for its EU GMP manufacturing facility in the UK. Cannabidiol produced from this facility is an NSF certified Dietary Ingredient (NSF/ANSI standard 173) and Raw Ingredient (Guideline 306), validating claims it has been tested for banned substances, heavy metals, microbials and pesticides.

"Brains Bio remains committed to providing quality, certified ingredients that ensure product integrity while meeting market demands. NSF certification reaffirms our commitment to supplying natural and sustainable cannabinoid ingredients in a rapidly growing marketplace,” said Ricky Brar, CEO and Chairperson of Brains Bio. "NSF certification allows us to supply CBD products tested for more than 280 athletically banned substances to our world-class roster of Olympians and athletes around the globe, giving them absolute assurance of purity."

This verification will allow the company to partner with leading global sports and nutrition brands such as Brain's deal with the UK’s largest vitamin company. This comes following the recent announcement from the Major League Baseball (MLB) allowing teams to work only with CBD brands which are NSF Certified for Sport®.

Through its wholly-owned subsidiary BSPG Laboratories, Brains has provided EU GMP CBD for clinical research around the globe for over seven years. With EU and UK-validated novel foods applications, the company now has 19 validated finished products in the UK and validation for its isolate across the EU. The company’s portfolio of proprietary formulations includes oils, sprays, topicals, gummies, capsules, water enhancers, and patches. its natural ingredients go through rigorous quality-control processes to ensure they meet the high-quality standards in the industry.

“We’re excited to announce that Brains Bio is the first company in the world to earn certification from NSF for a CBD ingredient,” said John Travis, Technical Manager for NSF Certified for Sport®. “NSF welcomes Brains Bio to the Certified for Sport® program. NSF is committed to protecting and improving human health worldwide. By meeting our rigorous Certified for Sport® requirements, Brains Bio is demonstrating its commitment to clean sport as well as quality, safety and good manufacturing processes.”

To earn NSF certification, Brains Bio completed a rigorous site inspection and ingredient testing process, verifying that good manufacturing practices are in place and its products have been tested for banned substances, pesticides, and heavy metals.

The certified plant-based EU GMP CBD products, manufacturing facility, and related marketing materials of Brains would bear the NSF Ingredient certification to show product manufacturers and brands that the ingredient quality has met rigorous standards. The above-mentioned list of NSF certifications can be found on NSF data base search domain (

Brains Bio’s market-leading position is further enhanced by its pharmaceutical regulatory package, which includes:

  • German DAC monograph compliant.
  • 36-Month stability data.
  • Over 350 commercial batches manufactured with resulting batch consistency and standardization data.
  • Approved IND filings with the US FDA.
  • Non-GMO, Kosher and Halal certified
  • Tested for banned substances by NSF, Informed Choice, and INRS (a WADA-certified lab)

Brains will also work with its partners and manufacturers, including the UK’s largest vitamin company, to supply EU GMP CBD products with NSF-certified ingredients while still meeting some of the highest quality standards, including ICHQ7, EU GMP, non-GMO, organic, and kosher, among others.

For media inquiries, please contact:

For investor relations, please contact:

Follow Brains Bio on Social:
Twitter: @BrainsBio, LinkedIn: @BrainsBio, Instagram: @BrainsPure

Brains Bioceutical is the leader in evidence-based Phyto-cannabinoid health solutions to enhance life and treatment options for all.

Brains Bio is a leading manufacturer of natural and pure active pharmaceutical ingredients (APIs), with a unique suite of licenses and registrations, Brains Bio is strategically positioned to take advantage of the complex regulatory environment, securing its first-mover and product quality advantage. Brains Bio is diversified across the pharmaceutical, medical, and nutraceutical sectors within the rapidly growing cannabinoid market, resulting in a strong and unique value proposition.

By partnering with industry leaders in the pharmaceutical and nutraceutical industries, Brains Bio is positioned for hyper-growth by leveraging the existing brand equity, resources, and experience of its major partners.

About NSF

NSF is an independent, global organization that facilitates standards development to minimize adverse health effects and protect the environment. With operations in 180 countries, NSF tests and certifies products for the food, water, health sciences, and consumer goods industries. Founded in 1944, NSF is committed to protecting human health and safety worldwide. NSF is a Pan American Health Organization and a World Health Organization Collaborating Centre on Water Quality, Food Safety, and Medical Device Safety.

To view this piece of content from, please give your consent at the top of this page.
To view this piece of content from, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified


PRESS RELEASE December 7th 2022 THE BOARD OF DIRECTORS OF RCI BANQUE SA APPOINTS PATRICK CLAUDE AS ACTING CHAIRMAN OF THE BOARD OF DIRECTORS OF RCI BANQUE SA The Nominations Committee of RCI Banque SA acknowledged the resignation of Clotilde Delbos as of December 31, 2022. Patrick Claude, VP Finance of Renault Group and member of the board of RCI Banque SA, has been proposed as acting Chairman of the Board of Directors of RCI Banque SA from January 1, 2023. The Board of Directors of RCI Banque SA, met on December 7 and very warmly thanked Clotilde Delbos her role as Chairman. The Board approved the appointment of Patrick Claude as acting Chairman of the Board of Directors of RCI Banque SA. Patrick Claude was also appointed as acting member of the Nominations Committee and the Remuneration Committee. The appointment of Patrick Claude as acting Chairman of the Board of Directors of RCI Banque SA will be subject to the approval of the European Central Bank. Patrick Claude is a graduate of

Ress Life Investments A/S publishes annual report7.12.2022 18:09:31 CET | Press release

Ress Life Investments A/S Corporate Announcement no. 44/2022 Annual Report 2021/22 CorporateAnnouncementno.44/2022:AnnualReport1October2021–30 September2022 Copenhagen, 7 December 2022 The Board of Directors and Management have today discussed and approved the Annual Report of Ress Life Investments A/S for the period 1 October 2021 – 30 September 2022. Key results and highlights: Ress Life Investments A/S realised a net profit before and after tax of USD 34,895,871 for the period 1 October 2021 – 30 September 2022. Net profit for the period corresponds to a net return on equity of 10.5% and an increase in net asset value of USD 229 per share. The increase in profit mainly relates to pay-outs of policies offset by administrative expenses and staff costs. The fair value of the Group’s investment assets increased from USD 255,262,257 at 30 September 2021 to USD 303,228,365 at 30 September 2022. The Group’s investments in treasury bills increased from US

PRESS RELEASE NACON: Ishtar Games, NACON’s indie label, announces new publishing line-up:7.12.2022 18:00:00 CET | Press release

Ishtar Games, NACON’s indie label, announces new publishing line-up After 17 years of developing games, Ishtar Games now also provides dedicated and passionate publishing support to its first group of studio partners. Lille, France, December 7th, 2022 — NACON is pleased to announce that its studio and indie-publishing label, Ishtar Games, developer behind Dead in Vinland, The Last Spell, reveals today the first games they will publish: Worlds of Aria (Ludogram Games), Spirited Thief (Koi Snowman Games), and their own developed game Lakeburg Legacies, all releasing in 2023. Take a look at the first line-up reveal trailer: "We are super excited to initiate our indie publishing label’s journey with Koi Snowman and Ludogram," Ishtar Games CEO and Creative Director Matthieu Richez said. "They have brought to us not only excellent games, but also great human beings to work with. I am convinced that this collaboration will bear fruit for all parties involved, whic

Ilkka Oyj – Acquisition of own shares on 7 December 20227.12.2022 18:00:00 CET | Press release

ILKKA OYJ, STOCK EXCHANGE RELEASE, 7 December 2022 at 19:00 EET IlkkaOyj – Acquisition of own shares on 7 December 2022 At Nasdaq Helsinki Ltd: Date7 December 2022Exchange transactionBuyShare trading codeILKKA2Amount, shares 1,350Average price/share, EUR3.6969Total cost, EUR4,990.82 The company holds a total of 2,917 of its own shares (ILKKA2) including the shares acquired on 7 December 2022. Detailed information concerning the acquisition is attached to this stock exchange release. On behalf of Ilkka Oyj DANSKE BANK A/S, FINLAND BRANCH Jonathan Nyberg Antti Väliaho Additional information Olli Pirhonen, CEO, Ilkka Oyj, tel. +358 40 766 5418 Attachment Ilkka buyback 7.12.2022

Rovio Entertainment Corporation: Repurchase of own shares on 7 December 20227.12.2022 17:45:00 CET | Press release

Rovio Entertainment Oyj STOCK EXCHANGE RELEASE 7.12.2022 at 18.45 EETRovio Entertainment Corporation - Repurchase of own shares on 7.12.2022Rovio Entertainment CorporationIn the Nasdaq HelsinkiDate7.12.2022Exchange transactionBUYShare trading codeROVIOAmount, shares32063Average price/share, EUR6,023788Total cost, EUR193140,71Rovio now holds a total of 6 548 427 shares including the shares repurchased on 7.12.2022On behalf of Rovio Entertainment CorporationOP Corporate Bank PLC Further information: Timo Rahkonen, VP Investor Relations & Corporate Strategy +358 40 730 3442 Distribution: Nasdaq Helsinki Ltd Key media About Rovio: Rovio Entertainment Corporation is a global mobile-first games company that creates, develops and publishes mobile games, which have been downloaded over 5 billion times. Rovio is best known for the global Angry Birds brand, which started as a popular mobile game in 2009, and has since evolved from games to various entertainment, a